Pedro Romero

List of Publications by Citations

310 papers	22,108 citations	78 h-index	138 g-index
322 ext. papers	25,121 ext. citations	9.2 avg, IF	6.43 L-index

#	Paper	IF	Citations
310	BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. *Journal of Experimental Medicine*, **1999**, 189, 1747-56	16.6	1089
309	TLR3 deficiency in patients with herpes simplex encephalitis. *Science*, **2007**, 317, 1522-7	33.3	842
308	Type I interferon inhibits interleukin-1 production and inflammasome activation. *Immunity*, **2011**, 34, 213-23	32.3	651
307	Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. *Journal of Clinical Investigation*, **2011**, 121, 2350-60	15.9	549
306	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *Journal of Clinical Investigation*, **2005**, 115, 739-46	15.9	497
305	Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. *Journal of Experimental Medicine*, **1998**, 188, 1641-50	16.6	443
304	Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. *Nature*, **1989**, 341, 323-6	50.4	433
303	Tumour immunity: effector response to tumour and role of the microenvironment. *Lancet, The*, **2008**, 371, 771-83	40	415
302	High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. *Journal of Experimental Medicine*, **1999**, 190, 705-15	16.6	402
301	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 6140-5	11.5	380
300	High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. *Journal of Experimental Medicine*, **1998**, 188, 1203-8	16.6	360
299	A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. *Nature*, **1988**, 332, 158-61	50.4	348
298	Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. *Cancer Research*, **2004**, 64, 2865-73	10.1	319
297	Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. *Arthritis and Rheumatism*, **2008**, 58, 2307-17		301
296	Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. *Journal of Immunology*, **2007**, 178, 4112-9	5.3	283
295	Induction of protective immunity against experimental infection with malaria using synthetic peptides. *Nature*, **1987**, 328, 629-32	50.4	254
294	Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. *European Journal of Immunology*, **2009**, 39, 1608-18	6.1	228

293	Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. *Journal of Clinical Investigation*, **2014**, 124, 1810-20	15.9	224
292	Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. *Nature Reviews Clinical Oncology*, **2019**, 16, 425-441	19.4	223
291	Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. *Journal of Immunology*, **2000**, 164, 1148-52	5.3	220
290	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. *Journal of Clinical Investigation*, **2010**, 120, 157-67	15.9	219
289	MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. *Immunity* , **2013**, 38, 742-53	32.3	204
288	CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. *Nature*, **1995**, 373, 353-6	50.4	202
287	CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. *International Immunology*, **1991**, 3, 579-85	4.9	194
286	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. *Nature Reviews Immunology*, **2014**, 14, 768-74	36.5	191
285	OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. *Nature Immunology*, **2000**, 1, 502-9	19.1	187
284	Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. *Cancer Research*, **2011**, 71, 5976-86	10.1	179
283	Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. *Oncogene*, **2002**, 21, 5213-23	9.2	173
282	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). *Cancer Immunology, Immunotherapy*, **2008**, 57, 303-15	7.4	172
281	Toll-like receptor 3 expressed by melanoma cells as a target for therapy?. *Clinical Cancer Research*, **2007**, 13, 4565-74	12.9	171
280	Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2307-12	11.5	170
279	In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. *Journal of Experimental Medicine*, **1999**, 190, 775-82	16.6	166
278	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. *International Journal of Cancer* , **1996**, 66, 162-9	7.5	163
277	"MIATA"-minimal information about T cell assays. *Immunity*, **2009**, 31, 527-8	32.3	161
276	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. *Frontiers in Immunology* , **2019**, 10, 925	8.4	159

275	New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. *Journal of Immunology*, **2006**, 177, 1670-8	5.3	149
274	Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. *Journal of Immunology* , **2010**, 184, 4936-46	5.3	148
273	Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. *Cancer Immunology Research*, **2014**, 2, 436-47	12.5	147
272	Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. *Blood*, **2003**, 102, 1779-87	2.2	142
271	The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. *Journal of Immunology*, **2009**, 182, 3510-21	5.3	141
270	Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. *Cancer Research*, **2012**, 72, 4629-41	10.1	141
269	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. *Immunological Reviews*, **2002**, 188, 81-96	11.3	132
268	Thymic selection generates a large T cell pool recognizing a self-peptide in humans. *Journal of Experimental Medicine*, **2002**, 195, 485-94	16.6	130
267	Toll-like receptors' two-edged sword: when immunity meets apoptosis. *European Journal of Immunology*, **2007**, 37, 3311-8	6.1	129
266	Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. *Journal of Immunology*, **2001**, 166, 7634-40	5.3	127
265	CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. *Journal of Immunology*, **2002**, 168, 1212-8	5.3	127
264	Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. *Immunity*, **2005**, 22, 117-29	32.3	126
263	Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. *Journal of Immunological Methods*, **2000**, 244, 81-9	2.5	126
262	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development. *Cell Metabolism*, **2019**, 29, 348-361.e6	24.6	119
261	The Human Vaccines Project: A roadmap for cancer vaccine development. *Science Translational Medicine*, **2016**, 8, 334ps9	17.5	115
260	Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3849-54	11.5	115
259	Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. *Journal of Immunotherapy*, **2010**, 33, 848-58	5	111
258	Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. *Journal of Experimental Medicine*, **1999**, 189, 895-906	16.6	109

257	Metabolic Control of CD8 T Cell Fate Decisions and Antitumor Immunity. *Trends in Molecular Medicine*, **2018**, 24, 30-48	11.5	104
256	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. *European Journal of Immunology*, **1999**, 29, 1990-9	6.1	102
255	Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538	7.2	101
254	Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. *Journal of Clinical Oncology*, **2003**, 21, 1562-73	2.2	100
253	Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. *Journal of Immunology*, **2006**, 177, 8708-13	5.3	98
252	NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells. *Journal of Immunology*, **2012**, 188, 3820-8	5.3	97
251	Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. *Journal of Immunology*, **2002**, 168, 1717-22	5.3	97
250	In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12457-61	11.5	93
249	A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. *Immunogenetics*, **1996**, 43, 377-83	3.2	90
248	In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. *European Journal of Immunology*, **2002**, 32, 731-41	6.1	88
247	TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. *Cancer Research*, **2011**, 71, 1607-14	10.1	87
246	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. *Blood*, **2007**, 110, 3564-72	2.2	87
245	Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. *Journal of Biological Chemistry*, **2012**, 287, 23068-78	5.4	86
244	Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. *Cancer Research*, **2004**, 64, 2192-8	10.1	85
243	Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. *Journal of Immunology*, **2009**, 182, 5140-51	5.3	84
242	Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. *Journal of Experimental Medicine*, **2002**, 196, 207-16	16.6	84
241	Sensitive and frequent identification of high avidity neo-epitope specific CD8 T cells in immunotherapy-naive ovarian cancer. *Nature Communications*, **2018**, 9, 1092	17.4	82
240	T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. *Journal of Immunological Methods*, **1992**, 155, 95-9	2.5	82

239	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. *Journal of Clinical Investigation*, **2013**, 123, 1044-56	15.9	82
238	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. *Cell Stem Cell*, **2019**, 24, 405-418.e7	18	81
237	Harmonization of immune biomarker assays for clinical studies. *Science Translational Medicine*, **2011** , 3, 108ps44	17.5	81
236	Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner. *Cell Reports*, **2016**, 14, 1206-1217	10.6	80
235	Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. *Journal of Immunology*, **2005**, 174, 1709-16	5.3	80
234	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge, Napoli, December 5th 2015 **2016**, 4,		78
233	Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. *Journal of Immunology*, **2008**, 180, 391-401	5.3	78
232	Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. *Journal of Immunology*, **2000**, 165, 533-8	5.3	77
231	Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. *Journal of Immunology*, **2002**, 168, 4231-40	5.3	76
230	Mitochondria-Endoplasmic Reticulum Contact Sites Function as Immunometabolic Hubs that Orchestrate the Rapid Recall Response of Memory CD8 T Cells. *Immunity*, **2018**, 48, 542-555.e6	32.3	75
229	The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. *Journal of Immunology*, **2001**, 167, 6165-70	5.3	74
228	Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. *Journal of Immunology*, **2001**, 167, 3276-84	5.3	73
227	Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. *Journal of Immunology*, **2000**, 165, 7253-61	5.3	73
226	CD8 beta increases CD8 coreceptor function and participation in TCR-ligand binding. *Journal of Experimental Medicine*, **1996**, 184, 2439-44	16.6	73
225	The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. *International Journal of Cancer*, **1993**, 54, 527-8	7.5	72
224	Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. *European Journal of Immunology*, **2001**, 31, 2642-51	6.1	71
223	Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. *Journal of Immunology*, **2000**, 164, 1125-31	5.3	70
222	Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. *International Journal of Cancer*, **2013**, 132, E85-93	7.5	69

221	Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. *Cancer Research*, **2013**, 73, 6597-608	10.1	68
220	Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. *Trends in Molecular Medicine*, **1998**, 4, 305-12		68
219	Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. *Journal of Immunology*, **2003**, 170, 5103-9	5.3	68
218	gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. *Clinical Cancer Research*, **2004**, 10, 668-80	12.9	68
217	Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. *Cancer Research*, **2002**, 62, 1743-50	10.1	67
216	A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. *Journal of Immunology*, **2006** , 177, 1338-48	5.3	66
215	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells **2019** , 7, 109		65
214	Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. *EBioMedicine*, **2016**, 4, 50-61	8.8	65
213	Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. *Journal of Immunology*, **2002**, 168, 1167-71	5.3	63
212	MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. *Journal of Biological Chemistry*, **2012**, 287, 9910-9922	5.4	62
211	Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. *International Journal of Cancer*, **1998**, 78, 699-706	7.5	62
210	Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1795-805	7.4	62
209	Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. *Cancer Immunology, Immunotherapy*, **2004**, 53, 249-55	7.4	62
208	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. *European Journal of Immunology*, **2011** , 41, 2217-28	6.1	59
207	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. *Journal of Translational Medicine*, **2014**, 12, 97	8.5	58
206	Virus-like particles induce robust human T-helper cell responses. *European Journal of Immunology*, **2012**, 42, 330-40	6.1	58
205	Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. *Journal of Translational Medicine*, **2011**, 9, 44	8.5	58
204	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. *Cancer Immunology, Immunotherapy*, **2009**, 58, 1701-13	7.4	58

203	Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. *International Journal of Cancer*, **2011**, 128, 2625-34	7.5	57
202	Siglec-9 Regulates an Effector Memory CD8 T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. *Cancer Immunology Research*, **2019**, 7, 707-718	12.5	56
201	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. *Frontiers in Immunology*, **2017**, 8, 1918	8.4	55
200	Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. *Journal of Immunology*, **2014**, 193, 1759-65	5.3	55
199	Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. *Journal of Immunology*, **2009**, 183, 319-31	5.3	55
198	High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. *Cancer Research*, **2004**, 64, 6319-26	10.1	55
197	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 T cells **2019**, 7, 257		54
196	CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. *Haematologica*, **2015**, 100, e257-60	6.6	53
195	Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. *Journal of Immunological Methods*, **2006**, 310, 136-48	2.5	52
194	Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. *Journal of Immunology*, **2003**, 171, 1844-9	5.3	52
193	The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. *Journal of Investigative Dermatology*, **1996**, 107, 63-7	4.3	51
192	Leishmania major infection in mice primes for specific major histocompatibility complex class I-restricted CD8+ cytotoxic T cell responses. *European Journal of Immunology*, **1994**, 24, 2813-7	6.1	51
191	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. *Frontiers in Immunology*, **2016**, 7, 573	8.4	50
190	The human T cell response to melanoma antigens. *Advances in Immunology*, **2006**, 92, 187-224	5.6	49
189	Structural analysis of TCR-ligand interactions studied on H-2Kd-restricted cloned CTL specific for a photoreactive peptide derivative. *Immunity*, **1995**, 3, 51-63	32.3	48
188	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors **2015**, 3, 15		47
187	Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. *Journal of Immunology*, **2002**, 169, 5696-707	5.3	47
186	Metabolic and epigenetic regulation of T-cell exhaustion. *Nature Metabolism*, **2020**, 2, 1001-1012	14.6	47

185	Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. *Journal of Immunology*, **2009**, 182, 6328-41	5.3	46
184	Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. *Journal of Immunology*, **2006**, 177, 6769-79	5.3	45
183	Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. *Journal of Immunology*, **2001**, 166, 4612-9	5.3	45
182	Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. *Cancer Research*, **2006**, 66, 1912-6	2.61	44
181	Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: advantages and limitations. *Cytometry*, **2002**, 48, 97-105		44
180	Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. *Seminars in Cancer Biology*, **2003**, 13, 461-72	12.7	44
179	Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. *International Immunology*, **1999**, 11, 1971-80	4.9	44
178	Specific binding of antigenic peptides to cell-associated MHC class I molecules. *Nature*, **1991**, 351, 72-4	50.4	44
177	Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. *Frontiers in Immunology*, **2018**, 9, 2076	8.4	43
176	Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. *Blood*, **2010**, 115, 5154-63	2.2	42
175	Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. *Journal of Immunology*, **2009**, 183, 5397-406	5.3	41
174	Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. *Trends in Immunology*, **2002**, 23, 325-8	14.4	41
173	Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. *Journal of Immunological Methods*, **2000**, 237, 159-73	2.5	41
172	Autocrine Adenosine Regulates Tumor Polyfunctional CD73CD4 Effector T Cells Devoid of Immune Checkpoints. *Cancer Research*, **2018**, 78, 3604-3618	10.1	40
171	Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. *European Journal of Immunology*, **2001**, 31, 459-66	6.1	40
170	Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. *Nature Immunology*, **2021**, 22, 746-756	19.1	40
169	Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. *Immunologic Research*, **2006**, 34, 67-87	4.3	39
168	Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. *International Immunopharmacology*, **2001**, 1, 1235-47	5.8	39

167	Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. *European Journal of Immunology*, **1994**, 24, 1458-62	6.1	39
166	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8 and CD4 T-cell responses with multiple specificities including a novel DR7-restricted epitope. *OncoImmunology*, **2016**, 5, e1216290	7.2	39
165	Recent advances and hurdles in melanoma immunotherapy. *Pigment Cell and Melanoma Research*, **2009**, 22, 711-23	4.5	38
164	Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. *Molecular Therapy*, **2008**, 16, 985-94	11.7	38
163	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. *Seminars in Immunology*, **2010**, 22, 144-54	10.7	37
162	Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. *Cancer Research*, **2009**, 69, 8085-93	10.1	37
161	Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. *Journal of Immunological Methods*, **2006**, 309, 192-9	2.5	37
160	Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. *Journal of Immunology*, **2007**, 179, 7406-14	5.3	37
159	A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. *Journal of Immunology*, **2001**, 167, 5852-61	5.3	37
158	Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. *Cancer Research*, **2003**, 63, 5601-6	10.1	37
157	Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. *Journal of Immunotherapy*, **2004**, 27, 298-308	5	36
156	F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1859-1868	8.8	35
155	Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells. *European Journal of Immunology*, **2000**, 30, 3079-88	6.1	35
154	HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. *Parasite Immunology*, **2000**, 22, 501-14	2.2	35
153	NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. *Nature Communications*, **2016**, 7, 10554	17.4	35
152	Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. *Cancer Immunity*, **2004**, 4, 4		35
151	Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. *European Journal of Immunology*, **2002**, 32, 2292-9	6.1	34
150	The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. *International Immunology*, **1991**, 3, 1035-42	4.9	34

149	CART cells are prone to Fas- and DR5-mediated cell death **2018**, 6, 71		33
148	Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 15010-5	11.5	33
147	Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. *MBio*, **2010**, 1,	7.8	32
146	Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. *Immunology Letters*, **1990**, 25, 27-31	4.1	32
145	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. *Nature Immunology*, **2019**, 20, 206-217	19.1	31
144	Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. *International Journal of Cancer*, **2001**, 95, 73-7	7.5	31
143	CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. *Immunology Letters*, **1995**, 46, 199-205	4.1	31
142	CD73 expression and clinical significance in human metastatic melanoma. *Oncotarget*, **2018**, 9, 26659-26669	5.9	31
141	Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. *Immunology and Cell Biology*, **2006**, 84, 318-30	5	30
140	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. *Clinical Cancer Research*, **2003**, 9, 669-77	12.9	30
139	Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. *Clinical and Experimental Immunology*, **2005**, 142, 292-302	6.2	29
138	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. *Science Advances*, **2021**, 7,	14.3	29
137	Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. *Cell Death and Disease*, **2016**, 7, e2243	9.8	28
136	Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. *Cancer Immunity*, **2003**, 3, 15		28
135	A microRNA profile of human CD8(+) regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes. *Journal of Translational Medicine*, **2014**, 12, 218	8.5	27
134	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. *Oncotarget*, **2016**, 7, 21199-221	3.3	27
133	Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. *International Journal of Cancer*, **2011**, 129, 762-72	7.5	26
132	Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. *Cancer Immunology, Immunotherapy*, **2007**, 56, 839-47	7.4	26

131	LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry. *Journal of Immunological Methods*, **2006**, 311, 31-46	2.5	26
130	High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. *European Journal of Immunology*, **2005**, 35, 2876-85	6.1	26
129	Toward improved immunocompetence of adoptively transferred CD8+ T cells. *Journal of Clinical Investigation*, **2005**, 115, 1467-9	15.9	26
128	Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. *International Journal of Cancer*, **2009**, 125, 649-55	7.5	25
127	In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. *Journal of Immunology*, **2007**, 179, 2368-79	5.3	25
126	Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. *Journal of Immunotherapy*, **2007**, 30, 240-50	5	25
125	Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. *Journal of Experimental Medicine*, **2021**, 218,	16.6	25
124	Enforced PGC-1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity. *Cellular and Molecular Immunology*, **2021**, 18, 1761-1771	15.4	24
123	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. *Cancer Immunology, Immunotherapy*, **2013**, 62, 747-60	7.4	24
122	A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. *Journal of Translational Medicine*, **2011**, 9, 108	8.5	24
121	Potential target antigens for immunotherapy in human pancreatic cancer. *Cancer Letters*, **2007**, 252, 290-8	9.9	24
120	TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency. *JCI Insight*, **2017**, 2,	9.9	24
119	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. *European Journal of Immunology*, **2000**, 30, 3165-70	6.1	23
118	Differential T cell receptor photoaffinity labeling among H-2Kd restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Labeling of the alpha-chain correlates with J alpha segment usage. *Journal of Experimental Medicine*, **1993**, 177, 1247-56	16.6	23
117	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. *Blood Advances*, **2019**, 3, 3674-3687	7.8	23
116	MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. *Cancer Immunology, Immunotherapy*, **2011**, 60, 23-35	7.4	22
115	Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. *European Journal of Immunology*, **2002**, 32, 3285-93	6.1	22
114	Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. *International Journal of Radiation Oncology Biology Physics*, **1999**, 45, 735-41	4	22

113	Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase. *Journal of Biological Chemistry*, **2010**, 285, 20481-91	5.4	21
112	HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. *Journal of Biological Chemistry*, **1996**, 271, 12463-71	5.4	21
111	Current state of vaccine therapies in non-small-cell lung cancer. *Clinical Lung Cancer*, **2008**, 9 Suppl 1, S28-36	4.9	21
110	Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope. *Journal of Biological Chemistry*, **2001**, 276, 43189-96	5.4	21
109	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. *Cancer Immunology, Immunotherapy*, **2014**, 63, 1199-211	7.4	20
108	Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. *Journal of Immunology*, **2006**, 176, 2330-6	5.3	20
107	A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. *Journal of Immunology*, **2007**, 179, 7635-45	5.3	20
106	Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. *Journal of Immunology*, **2004**, 173, 6033-40	5.3	20
105	IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. *Journal of Immunology*, **2016**, 197, 85-96	5.3	20
104	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. *Cancer Immunology, Immunotherapy*, **2019**, 68, 467-478	7.4	20
103	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. *Frontiers in Immunology*, **2019**, 10, 2121	8.4	19
102	PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. *Journal of Immunology*, **2018**, 201, 792-803	5.3	19
101	CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival. *Cancer Research*, **2019**, 79, 5245-5259	10.1	19
100	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. *Clinical Cancer Research*, **2017**, 23, 717-725	12.9	19
99	Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. *Blood*, **2003**, 102, 1241-8	2.2	19
98	MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif. *International Immunology*, **1993**, 5, 1489-92	4.9	19
97	MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. *Cancer Immunology Research*, **2019**, 7, 1013-1024	12.5	18
96	Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines. *Vaccine*, **2012**, 30, 388-97	4.1	18

95	Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. *Journal of Immunology*, **2009**, 182, 6718-26	5.3	18
94	Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1979-91	7.4	18
93	Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. *Journal of Immunotherapy*, **2007**, 30, 533-43	5	18
92	Melanoma immunotherapy: past, present, and future. *Current Pharmaceutical Design*, **2005**, 11, 3461-73	3.3	18
91	Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. *Cancer Research*, **2002**, 62, 2058-63	10.1	18
90	Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 15318-23	11.5	17
89	Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth. *Frontiers in Oncology*, **2018**, 8, 356	5.3	17
88	Curtailed T-cell activation curbs effector differentiation and generates CD8 T cells with a naturally-occurring memory stem cell phenotype. *European Journal of Immunology*, **2017**, 47, 1468-1476	6.1	16
87	Toll-like receptor 3 is necessary for dsRNA adjuvant effects. *Vaccine*, **2009**, 27, 1841-7	4.1	16
86	Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. *Journal of Immunotherapy*, **2010**, 33, 723-34	5	16
85	Differential roles of T cell receptor alpha and beta chains in ligand binding among H-2Kd-restricted cytolytic T lymphocyte clones specific for a photoreactive Plasmodium berghei circumsporozoite peptide derivative. *Journal of Biological Chemistry*, **1997**, 272, 8505-14	5.4	16
84	IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. *Journal of Immunology*, **2007**, 178, 3566-74	5.3	16
83	Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. *Journal of Immunology*, **2004**, 172, 2773-7	5.3	16
82	Vaccination route matters for mucosal tumors. *Science Translational Medicine*, **2013**, 5, 172fs4	17.5	15
81	Methods for the ex vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. *Methods in Molecular Medicine*, **2005**, 109, 265-84		15
80	Recent advances in tumour antigen-specific therapy: in vivo veritas. *International Journal of Cancer*, **2005**, 113, 173-8	7.5	15
79	Rationale for immunological approaches to breast cancer therapy. *Breast*, **2018**, 37, 187-195	3.6	14
78	Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. *International Journal of Cancer*, **2010**, 126, 2469-78	7.5	14

77	Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. *European Journal of Immunology*, **2006**, 36, 1805-14	6.1	14
76	Distinct mechanisms control human naive and antigen-experienced CD8+ T lymphocyte proliferation. *Journal of Immunology*, **2006**, 176, 2173-82	5.3	14
75	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. *European Journal of Cancer*, **2020**, 135, 173-182	7.5	13
74	Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. *Journal of Leukocyte Biology*, **2020**, 108, 723-737	6.5	13
73	Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. *Journal of Immunotherapy*, **2009**, 32, 875-83	5	13
72	Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. *International Immunology*, **2008**, 20, 1087-96	4.9	13
71	Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. *International Journal of Cancer*, **2002**, 99, 82-7	7.5	13
70	Amino Acid Identity and/or Position Determines the Proteasomal Cleavage of the HLA-A*0201-restricted Peptide Tumor Antigen MAGE-3271279. *Journal of Biological Chemistry*, **2000**, 275, 26892-26897	5.4	13
69	Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. *Frontiers in Immunology*, **2019**, 10, 294	8.4	13
68	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. *Frontiers in Immunology*, **2020**, 11, 340	8.4	12
67	Immunosuppressive Mediators Impair Proinflammatory Innate Lymphoid Cell Function in Human Malignant Melanoma. *Cancer Immunology Research*, **2020**, 8, 556-564	12.5	12
66	Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. *Journal of Urology*, **2014**, 191, 814-22	2.5	12
65	Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. *OncoImmunology*, **2012**, 1, 467-530	7.2	12
64	Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. *PLoS ONE*, **2013**, 8, e78686	3.7	12
63	Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARAgonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth. *Cancer Research*, **2018**, 78, 6447-6461	10.1	12
62	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine **2014**, 2, 39		11
61	High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. *Clinical Cancer Research*, **2019**, 25, 4320-4331	12.9	10
60	Local immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. *OncoImmunology*, **2015**, 4, e1016697	7.2	10

59	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. *OncoImmunology*, **2015**, 4, e1029702	7.2	10
58	Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. *Seminars in Immunopathology*, **1996**, 18, 185-98		10
57	Piezoresistive Membrane Surface Stress Sensors for Characterization of Breath Samples of Head and Neck Cancer Patients. *Sensors*, **2016**, 16,	3.8	10
56	Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. *Cancer Immunity*, **2002**, 2, 14		10
55	Epitope located N-glycans impair the MHC-I epitope generation and presentation. *Electrophoresis*, **2016**, 37, 1448-60	3.6	9
54	Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans. *European Journal of Immunology*, **2014**, 44, 2567-70	6.1	9
53	Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen. *International Journal of Cancer*, **1997**, 72, 1045-55	7.5	9
52	Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1795-805	7.4	9
51	Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. *Cellular Immunology*, **2004**, 227, 93-102	4.4	9
50	Efficient in vivo induction of CTL by cell-associated covalent H-2Kd-peptide complexes. *Journal of Immunological Methods*, **1994**, 171, 73-84	2.5	9
49	Disease-driven T cell activation predicts immune responses to vaccination against melanoma. *Cancer Immunity*, **2003**, 3, 12		8
48	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8 T cells. *OncoImmunology*, **2017**, 6, e1318234	7.2	7
47	Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. *Clinical and Developmental Immunology*, **2013**, 2013, 875343		7
46	Therapeutic cancer vaccines based on molecularly defined human tumor antigens. *Vaccine*, **2002**, 20 Suppl 4, A2-7	4.1	7
45	miR-155 Overexpression in OT-1 CD8 T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. *Molecular Therapy - Oncolytics*, **2020**, 16, 111-123	6.4	7
44	PPAR? drives IL-33-dependent ILC2 pro-tumoral functions. *Nature Communications*, **2021**, 12, 2538	17.4	7
43	Gain of HIF1 Activity and Loss of miRNA Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis. *Cancer Research*, **2021**, 81, 594-605	10.1	7
42	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients **1999**, 29, 1990		7

41	What is the influence of vaccination's routes on the regression of tumors located at mucosal sites?. *OncoImmunology*, **2012**, 1, 242-243	7.2	6
40	Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients. *Journal of Investigative Dermatology*, **2008**, 128, 1977-80	4.3	6
39	Fibroblast Activation Protein-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. *Clinical Cancer Research*, **2021**, 27, 4036-4053	12.9	6
38	CD40 Agonist Targeted to Fibroblast Activation Protein Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. *Clinical Cancer Research*, **2021**, 27, 4054-4065	12.9	6
37	An Immunomodulatory Gallotanin-Rich Fraction From Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. *Frontiers in Immunology*, **2020**, 11, 584959	8.4	5
36	Structured reporting of T cell assay results. *Cancer Immunity*, **2013**, 13, 13		5
35	Tinkering with nature: the tale of optimizing peptide based cancer vaccines. *Cancer Treatment and Research*, **2005**, 123, 267-91	3.5	5
34	Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. *International Journal of Cancer*, **2002**, 99, 201-6	7.5	4
33	On the significance of CD8 alpha alpha expression for T cell memory. *European Journal of Immunology*, **2005**, 35, 3092-4	6.1	4
32	Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. *Tissue Antigens*, **1999**, 53, 519-26		4
31	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. *Vaccines*, **2021**, 9,	5.3	4
30	The Vast Universe of T Cell Diversity: Subsets of Memory Cells and Their Differentiation. *Methods in Molecular Biology*, **2017**, 1514, 1-17	1.4	3
29	The role of the reporting framework MIATA within current efforts to advance immune monitoring. *Journal of Immunological Methods*, **2014**, 409, 6-8	2.5	3
28	Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. *PLoS ONE*, **2013**, 8, e65590	3.7	3
27	An optimized antigen-protein fusion. *Nature Biomedical Engineering*, **2020**, 4, 583-584	19	2
26	An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. *Cancer Immunity*, **2008**, 8, 6		2
25	Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. *Methods in Molecular Biology*, **2010**, 626, 231-49	1.4	2
24	The Era of Cytotoxic CD4 T Cells.. *Frontiers in Immunology*, **2022**, 13, 867189	8.4	2

23	Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine **2012**, 417-440		1
22	T Cells in Tumor Immunity **2002**, 40-55		1
21	Tumor cell recognition efficiency by T cells. *PLoS Medicine*, **2005**, 2, e77; author reply e95	11.6	1
20	Degeneracy instead of specificity: is this a solution to cancer immunotherapy?. *Trends in Immunology*, **2002**, 23, 344	14.4	1
19	Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. *Annals of Oncology*, **1996**, 7, 339-42	10.3	1
18	Lighting up the tumor fire with low-dose irradiation.. *Trends in Immunology*, **2022**,	14.4	1
17	N-acetyl-L-cysteine Exhibits Antitumoral Activity by Increasing Tumor Necrosis Factor □Dependent T-Cell Cytotoxicity. *Blood*, **1997**, 90, 1124-1132	2.2	1
16	Recombinant fusion proteins for targeting dendritic cell subsets in therapeutic cancer vaccine. *Methods in Enzymology*, **2020**, 632, 521-543	1.7	1
15	Detecting and analyzing murine innate lymphoid cells. *Methods in Enzymology*, **2020**, 631, 329-342	1.7	1
14	CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 209-214	5.1	1
13	Human primed ILCPs support endothelial activation through NF-□B signaling. *ELife*, **2021**, 10,	8.9	1
12	Circulating MELAN-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype **1998**, 78, 699		1
11	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients **1999**, 29, 1990		1
10	Lack of tumor recognition by hTERT peptide 540□548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing **2001**, 31, 2642		1
9	Peptide and Protein-Based Cancer Vaccines **2013**, 111-146		1
8	CD8 T Lymphocytes in Antitumor Immunity **2016**, 434-440		
7	JITC launches a new section: commentary and editorials **2015**, 3, 28		
6	Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer **2015**, 3, 49		

5	Melanoma Vaccines **2012**, 207-232	
4	Modulation of proteasomal activity in vitro induces the generation of an HLA-A?0201 specific CTL-defined epitope derived from the melanoma-associated antigen MAGE-3 **2002**, 693-694	
3	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. *Blood*, **2015**, 126, 1019-1019	2.2
2	Generation of affinity ranged antigen-expressing tumor cell lines. *Methods in Enzymology*, **2020**, 632, 503-519	1.7
1	Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells. *Methods in Enzymology*, **2020**, 631, 77-90	1.7